Amgen Stock Surges on Breakthrough Sjögren’s Disease Trial Results

Amgen's stock surged 4% in premarket hours on Tuesday after the biotech company announced positive topline data from its Phase 3 clinical trial evaluating dazodalibep, an investigational therapy for Sjögren's disease. The OASIZ 301 trial achieved its primary goal, demonstrating statistically significant improvements in systemic disease severity at the 48-week mark.

Data revealed meaningful improvements beginning at Week 4 and were maintained throughout the entire 48-week observation period. Amgen's executive vice president of research and development, Jay Bradner, noted that both the rapid onset and sustained nature of the trial outcomes strengthened the organization's belief in the therapeutic candidate.

No FDA-approved medications currently exist for Sjögren's disease, positioning dazodalibep as a pioneering therapeutic option. The clinical study included approximately 621 participants diagnosed with moderate-to-severe systemic Sjögren's disease.